Ranbaxy Gets Us Nod For Amoxicillin Tablets

Ranbaxy Laboratories Ltd (RLL) today announced that it has received US Food and Drug Administration (FDA) approval to market DisperMox, amoxicillin tablets for oral suspension in 200 mg and 400 mg strength.

DisperMox, a pending trademark of Ranbaxy, embodies a new dosage form of amoxicillin designed to build on the strong efficacy, safety, and tolerability features of Amoxil (a registered trademark of GlaxoSmithKline), the company said in a statement here today.

It would also provide additional benefits in terms of dosage accuracy and is available as a pleasant strawberry flavour.

The product is administered as a convenient, twice-a-day dosage regimen and since it is a tablet, not requiring refrigeration, it can be taken anywhere, the statement added.

 

DisperMox will be launched in the US by October 2003 and will be marketed and distributed by Ranbaxy Pharmaceuticals Inc, a wholly owned arm of Ranbaxy, through wholesalers, distributors and pharmacies, the statement said.